Drugs / recombinant P-selectin glycoprotein ligand Ig
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00298168 | May 2006 → Sep 2007 | kidney disorder | Y's Therapeutics, Inc. | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant P-selectin glycoprotein ligand Ig | “intervention trial with the selectin antagonist YSPSL (recombinant P-selectin glycoprotein ligand Ig).” PMID 21114535 ↗ Nov 2010 |
| Known as | YSPSL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00298168 ↗ |
| Action | Inhibit | “It has been reported that YSPSL (rPSGL-Ig) blocks P-selectin and, to a lesser degree, E- and L-selectin.” NCT00298168 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant P-selectin glycoprotein ligand IgG fusion protein, rPSGL-Ig (YSPSL), a fusion protein of human P-selectin ligand and IgG1-Fc, blocks leukocyte adhesion and protects...” PMID 20573162 ↗ Jun 2010 |
| Route | Intravenous | “YSPSL administered intravenously (IV)” NCT00298168 ↗ |